MX357977B - Medio de cultivo celular libre de suero. - Google Patents

Medio de cultivo celular libre de suero.

Info

Publication number
MX357977B
MX357977B MX2015013176A MX2015013176A MX357977B MX 357977 B MX357977 B MX 357977B MX 2015013176 A MX2015013176 A MX 2015013176A MX 2015013176 A MX2015013176 A MX 2015013176A MX 357977 B MX357977 B MX 357977B
Authority
MX
Mexico
Prior art keywords
serum
culture medium
cell culture
free cell
ornithine
Prior art date
Application number
MX2015013176A
Other languages
English (en)
Other versions
MX2015013176A (es
Inventor
Oshodi Shadia
Johnson Amy
Lawrence Shawn
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357977(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2015013176A publication Critical patent/MX2015013176A/es
Publication of MX357977B publication Critical patent/MX357977B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/16—Magnesium; Mg chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un medio de cultivo mejorado de células de animal, libre de suero, que se puede usar para la producción de una proteína de interés. Se puede añadir ornitina, o una combinación de ornitina y putrescina al medio libre de suero o medio definido químicamente para mejorar la densidad de las células viables, para reducir el tiempo de duplicación de las células, y para aumentar la producción de una proteína de interés.
MX2015013176A 2013-03-15 2014-03-14 Medio de cultivo celular libre de suero. MX357977B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790136P 2013-03-15 2013-03-15
US14/211,245 US20140273095A1 (en) 2013-03-15 2014-03-14 Serum-Free Cell Culture Medium
PCT/US2014/028501 WO2014144198A1 (en) 2013-03-15 2014-03-14 Serum-free cell culture medium

Publications (2)

Publication Number Publication Date
MX2015013176A MX2015013176A (es) 2016-04-07
MX357977B true MX357977B (es) 2018-08-01

Family

ID=51528781

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015013176A MX357977B (es) 2013-03-15 2014-03-14 Medio de cultivo celular libre de suero.
MX2021001859A MX2021001859A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.
MX2021008627A MX2021008627A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021001859A MX2021001859A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.
MX2021008627A MX2021008627A (es) 2013-03-15 2015-09-15 Medio de cultivo celular libre de suero.

Country Status (22)

Country Link
US (5) US20140273095A1 (es)
EP (4) EP3378932A1 (es)
JP (5) JP6781039B2 (es)
KR (6) KR102229380B1 (es)
CN (2) CN113481148A (es)
AR (1) AR095196A1 (es)
AU (4) AU2014227804B2 (es)
BR (2) BR122020021864B1 (es)
CA (5) CA2906768C (es)
DK (1) DK2970876T3 (es)
EA (3) EA202190326A3 (es)
ES (1) ES2682929T3 (es)
HK (1) HK1213289A1 (es)
HU (1) HUE040233T2 (es)
IL (5) IL281515B2 (es)
MX (3) MX357977B (es)
MY (1) MY175957A (es)
PL (1) PL2970876T3 (es)
PT (1) PT2970876T (es)
SG (3) SG10202107444XA (es)
TW (4) TWI701333B (es)
WO (1) WO2014144198A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015148515A1 (en) * 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US20180355304A1 (en) * 2015-12-03 2018-12-13 Merck Patent Gmbh Chemically defined media for the growth or detection of microorganisms
KR20180047404A (ko) * 2016-10-31 2018-05-10 삼성바이오에피스 주식회사 세포 배양 배지에서 원치 않는 배양 부산물을 감소시키는 공정
CN108220228A (zh) * 2016-12-09 2018-06-29 上海迈泰君奥生物技术有限公司 无血清细胞培养基及高效表达重组蛋白质的方法
CN106635953B (zh) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 无血清无蛋白细胞培养基
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
SG11201912548XA (en) * 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
CN108103003B (zh) * 2017-12-12 2021-03-05 四川百诺吉科技有限公司 一种适应pk-15全悬浮生长的无血清培养基及其制备方法和应用于pk-15细胞的全悬浮驯化方法
WO2019135238A1 (en) * 2018-01-03 2019-07-11 Technion Research & Development Foundation Limited Naive pluripotent stem cell media
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US20220204920A1 (en) * 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用
WO2021112927A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
EP4281542A1 (en) * 2021-01-20 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
KR20220127465A (ko) 2021-03-11 2022-09-20 주식회사 만도 조향 제어 장치 및 방법

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0082974B1 (en) 1981-12-24 1986-05-14 Asahi Kasei Kogyo Kabushiki Kaisha Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
DE3801236A1 (de) 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
JPH03504330A (ja) 1988-12-14 1991-09-26 アメリカ合衆国 ヒト肝上皮細胞系のための細胞培地
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5426699A (en) 1993-10-25 1995-06-20 Antec Corporation Method and apparatus for digitizing a scrambled analog video signal
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
HUP0202974A3 (en) 1995-07-17 2005-05-30 Fraunhofer Ges Forschung Metal-containing ribonucleotide polypeptides
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6043092A (en) 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6146847A (en) 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
CA2318376A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN1114619C (zh) * 1999-06-25 2003-07-16 中国科学院上海细胞生物学研究所 小鼠杂交瘤株Hepama－1分泌的肝癌鼠源单克隆抗体的制备方法
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CN1240300C (zh) 2001-03-05 2006-02-08 科学与工业研究会 由大豆粉制备蛋白水解物的方法
EP1321515A1 (en) 2001-12-21 2003-06-25 Ingenium Pharmaceuticals AG Method of culturing cells
CN1180080C (zh) * 2002-01-18 2004-12-15 中国科学院上海细胞生物学研究所 一种改进的肝癌鼠源单克隆抗体的制备方法
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
DK1531666T3 (da) 2002-05-29 2014-01-13 Regeneron Pharma Inducerbart eukaryot-ekspressionssystem
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
WO2004104186A1 (en) 2003-05-15 2004-12-02 Wyeth Restricted glucose feed for animal cell culture
US7303694B2 (en) 2003-07-17 2007-12-04 Wisconsin Alumni Research Foundation Liquid crystals with reduced toxicity and applications thereof
WO2005028626A2 (en) 2003-09-18 2005-03-31 Raven Biotechnologies, Inc. Cell culture media
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
CA2585547A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL3121266T3 (pl) * 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
DE602007008627D1 (de) * 2006-02-14 2010-10-07 Genetix Ltd Zellkulturmedium
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN100482786C (zh) * 2007-12-28 2009-04-29 天津百若克医药生物技术有限责任公司 一种人胚肾293细胞扩增无蛋白培养基
CN102317440B (zh) * 2008-01-09 2014-12-03 塞尔卡有限公司 改进的培养基添加剂及其应用方法
CA2737580A1 (en) * 2008-09-26 2010-04-01 Schering Corporation High titer antibody production
EP2356247B2 (en) 2008-11-12 2019-05-15 Baxalta Incorporated Method of producing serum-free insulin-free factor vii
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
HUE038596T2 (hu) 2009-06-02 2018-10-29 Regeneron Pharma Fukoziláció-hiányos sejtek
CN101603026B (zh) 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RS60983B1 (sr) 2010-02-24 2020-11-30 Chiesi Farm Spa Postupak za proizvodnju i prečišćavanje lizozomske alfa-manozidaze
AU2011246502B2 (en) 2010-04-26 2014-08-28 Novartis Ag Improved cell cultivation process
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
TWI670073B (zh) * 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
BR112013018751B1 (pt) 2010-12-28 2021-01-05 Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.) método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EP2780368B1 (en) 2011-11-14 2018-01-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP6090735B2 (ja) 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
CA2875294C (en) 2012-04-25 2021-06-08 Riken Cell preparation containing myocardium-committed cell
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
IN2014DN10441A (es) 2012-06-21 2015-08-21 Baxter Int
JP2015526430A (ja) 2012-08-02 2015-09-10 サノフイ アフリベルセプトまたはｚｉｖ−アフリベルセプトを含む製造物品
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
SG10201901708SA (en) 2012-10-23 2019-03-28 Genzyme Corp Perfusion culturing methods and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
MX367025B (es) 2013-02-22 2019-08-02 Genzyme Corp Metodos de cultivo por perfusion con microportadores y usos de los mismos.
NZ711654A (en) 2013-03-12 2021-07-30 Cmc Icos Biologics Inc Improved recombinant protein expression using a hybrid chef1 promoter
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014159633A1 (en) 2013-03-14 2014-10-02 Medimmune, Llc Recombinant polypeptide production
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US20160237400A1 (en) 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
EP3004368B1 (en) 2013-05-29 2019-09-18 F.Hoffmann-La Roche Ag Quantitative control of sialylation
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US10513723B2 (en) 2014-01-13 2019-12-24 Amgen Inc. Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
NZ726602A (en) 2014-05-05 2024-05-31 Regeneron Pharmaceuticals Inc Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP2017516484A (ja) 2014-06-03 2017-06-22 ルピン・リミテッド タンパク質生産のための細胞培養工程
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
SG11201705743YA (en) 2015-04-01 2017-08-30 Boehringer Ingelheim Int Cell culture medium
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein

Also Published As

Publication number Publication date
HUE040233T2 (hu) 2019-02-28
EP2970876B1 (en) 2018-07-11
MX2021008627A (es) 2022-06-14
AU2021205088B2 (en) 2022-09-22
JP2019150037A (ja) 2019-09-12
EA037568B1 (ru) 2021-04-15
ES2682929T3 (es) 2018-09-24
IL241195B (en) 2019-05-30
KR20210031778A (ko) 2021-03-22
JP2016514452A (ja) 2016-05-23
TWI629359B (zh) 2018-07-11
CA3238121A1 (en) 2014-09-18
CA2906768A1 (en) 2014-09-18
JP2022172390A (ja) 2022-11-15
KR102229380B1 (ko) 2021-03-18
EP2970876A1 (en) 2016-01-20
PL2970876T3 (pl) 2018-11-30
JP7429743B2 (ja) 2024-02-08
IL289724A (en) 2022-03-01
EA202190326A3 (ru) 2021-09-30
NZ711935A (en) 2021-04-30
AU2020200052A1 (en) 2020-01-30
AU2022211862A1 (en) 2022-08-25
KR102278316B1 (ko) 2021-07-19
MX2015013176A (es) 2016-04-07
CN105143444A (zh) 2015-12-09
AU2014227804A1 (en) 2015-09-24
KR20220116571A (ko) 2022-08-23
IL281515B1 (en) 2024-01-01
BR122020021864B1 (pt) 2022-09-20
US20140273095A1 (en) 2014-09-18
JP2021180682A (ja) 2021-11-25
AR095196A1 (es) 2015-09-30
TWI782295B (zh) 2022-11-01
EP3919611A1 (en) 2021-12-08
AU2014227804B2 (en) 2020-01-30
SG10202107444XA (en) 2021-08-30
CA3135232C (en) 2024-06-18
PT2970876T (pt) 2018-10-22
TW201502273A (zh) 2015-01-16
IL289724B2 (en) 2023-08-01
HK1213289A1 (zh) 2016-06-30
US20200149081A1 (en) 2020-05-14
AU2021205088A1 (en) 2021-08-12
SG11201507072TA (en) 2015-10-29
US11332771B2 (en) 2022-05-17
CN113481148A (zh) 2021-10-08
CA3188491A1 (en) 2014-09-18
EP4159841A1 (en) 2023-04-05
KR20150128785A (ko) 2015-11-18
TW201835325A (zh) 2018-10-01
US11970724B2 (en) 2024-04-30
TW202041672A (zh) 2020-11-16
EA202190326A2 (ru) 2021-05-31
KR20240065185A (ko) 2024-05-14
EA201591817A1 (ru) 2016-05-31
JP2024001357A (ja) 2024-01-09
US20210332402A1 (en) 2021-10-28
JP6781039B2 (ja) 2020-11-04
IL281515A (en) 2021-04-29
US20220228187A1 (en) 2022-07-21
US20220372436A1 (en) 2022-11-24
BR112015022682A2 (pt) 2017-07-18
BR112015022682B1 (pt) 2023-03-28
CA3238123A1 (en) 2014-09-18
KR20200119894A (ko) 2020-10-20
TW202325723A (zh) 2023-07-01
IL264499A (en) 2019-02-28
TWI701333B (zh) 2020-08-11
EA202191602A2 (ru) 2021-08-31
MY175957A (en) 2020-07-16
CA2906768C (en) 2022-08-30
IL289724B1 (en) 2023-04-01
IL281515B2 (en) 2024-05-01
KR102166166B1 (ko) 2020-10-15
IL241195A0 (en) 2015-11-30
KR20210090732A (ko) 2021-07-20
EA202191602A3 (ru) 2021-12-31
SG10201707153UA (en) 2017-10-30
DK2970876T3 (en) 2018-08-13
WO2014144198A1 (en) 2014-09-18
IL300911A (en) 2023-04-01
JP6944969B2 (ja) 2021-10-06
EP3378932A1 (en) 2018-09-26
CA3135232A1 (en) 2014-09-18
AU2020200052B2 (en) 2023-01-19
MX2021001859A (es) 2021-04-19

Similar Documents

Publication Publication Date Title
MX2021001859A (es) Medio de cultivo celular libre de suero.
MX2022003477A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2015017928A (es) Montajes de mezclado incluyendo impulsores magneticos.
MX2020002544A (es) Sales de glicopirrolato.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
MX2020013695A (es) Biorreactores de peque?o volumen con volumenes de trabajo sustancialmente constantes y sistemas y metodos relacionados.
HK1213179A1 (zh) 細胞培養培養基和抗體生產方法
MX369522B (es) Metodos de cultivo por perfusión con microportadores y usos de los mismos.
MX2019009189A (es) Metodos de cultivo por perfusion con microportadores y usos de los mismos.
BR112016016508A2 (pt) Método de bioconversão para produção de capsaicinoides
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MY180179A (en) A novel modified ornithine decarboxylase protein and a use thereof
EP3158077A4 (en) Cell culture methods and media comprising n-acetylcysteine
BR112016006063A2 (pt) método para clarificação de uma colheita de cultura celular em bruto
MX2016008345A (es) Produccion de anticuerpos ex vivo.
MY167644A (en) Recording medium
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
MX2016013363A (es) Metodo para aumentar la capacidad de sintesis de biomasa de microorganismos y microorganismos modificados a partir de ellos.
UA93152U (uk) Спосіб одержання екзополісахариду
UA93516U (uk) Спосіб підвищення антистресової дії пробіотиків
TW201612309A (en) Solid medium for culturing Ganoderma strains and application thereof

Legal Events

Date Code Title Description
FG Grant or registration